Condition: Acute Coronary Syndrome · Unstable Angina · ST Elevation Myocardial Infarction · Sponsor: Beijing Anzhen Hospital
This trial is designed to evaluate whether low-dose colchicine, in addition to standard treatment recommended by guidelines, further reduces the risk of major adverse cardiovascular events in patients with acute coronary syndromes (ACS) through a prospective, randomized, double-blind, placebo-controlled clinical trial.
This description comes directly from the study's public registry record.
Yujie Zhou, PhD, MD · 8613901330652 · azzyj12@163.com
Xiaoteng Ma, MD · 8618810616459 · maxiaotengai@163.com
Always discuss trial participation with your own doctor first.
| Beijing Anzhen Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06215989